Novavax’s Covid-19 jab is more than 90% effective, including against coronavirus variants, the vaccine maker said on June 14 (2021) after a large-scale study.
The jab “demonstrated 100% protection against moderate and severe disease, 90.4% efficacy overall”, the company said in a statement.
It added that “the study enrolled 29,960 participants across 119 sites in the United States and Mexico to evaluate efficacy, safety and immunogenicity.”
The US-based company said it intended to apply for regulatory approval by the third quarter of this year (2021).
After that, it said, it would be on course to make 100 million doses per month by the end of the third quarter and 150 million doses per month by the end of the year.
While some rich countries have made progress on vaccinating their populations, there remain concerns that many poorer countries are being left out of the global inoculation drive.
Vaccination rates in the world’s poorest nations are far behind the Group of Seven (G7) industrialised powers and other wealthy states.
In terms of doses administered so far, the imbalance between the G7 and low-income countries, as defined by the World Bank, is 73 to one.
Novavax’s vaccine – formally known as NVX-CoV2373 – can be stored in normal refrigerators.
The company said it was “stored and stable at 2°-8°C, allowing the use of existing vaccine supply chain channels for its distribution.
“In theory at least, this means the shots should be more easily transported and administered in countries with less well-developed health infrastructures.”
The two-dose vaccine consists of modified SARS-CoV-2 viral spike proteins encased in a synthetic lipid nanoparticle, accompanied by a saponin-based adjuvant.
Doses are to be given three weeks apart. – AFP Relaxnews